000			02216nam a2200457 i 4500
999			_c272589 _d272589
001			on1039079947
003			OCoLC
005			20180730153152.0
006			m o d f
007			cr bn||||a||||
008			180607s2018 dcu ob f000 0 eng c
040			_aPUCPR _beng _erda _epn _cGPO _dGPO _dMvI
042			_apcc
043			_an-us---
074			_a1027-C (online)
086	0		_aY 4.V 64/3:115-4
088			_aSerial no. 115-4 (United States. Congress. House. Committee on Veterans' Affairs)
099			_aY 4.V 64/3:115-4
110	1		_aUnited States. _bCongress. _bHouse. _bCommittee on Veterans' Affairs. _bSubcommittee on Oversight and Investigations,
245	1	0	_aAssessing VA's risks for drug diversion : _bhearing before the Subcommittee on Oversight and Investigations of the Committee on Veterans' Affairs, U.S. House of Representatives, One Hundred Fifteenth Congress, first session, Monday, February 27, 2017.
246	3		_aAssessing Veterans Affairs' risks for drug diversion
264		1	_aWashington : _bU.S. Government Publishing Office, _c2018.
300			_a1 online resource (iii, 41 pages)
336			_btxt
337			_bc _2rdamedia
338			_bcr _2rdacarrier
500			_a"Serial no. 115-4."
500			_aCRDP Program record.
504			_aIncludes bibliographical references.
588			_aDescription based on online resource; title from PDF title screen (govinfo web site, viewed on June 7, 2018).
776	0	8	_iPrint version: _aUnited States. Congress. House. Committee on Veterans' Affairs. Subcommittee on Oversight and Investigations. _tAssessing VA's risks for drug diversion _w(OCoLC)1039079922
856	4	0	_uhttp://purl.fdlp.gov/GPO/gpo92795
050		4	_aKF27 _b.V462 2017
610	1	0	_aUnited States. _bVeterans Health Administration _xRules and practice.
650		0	_aHospital pharmacies _xSecurity measures _zUnited States _xEvaluation.
650		0	_aVeterans' hospitals _xSecurity measures _zUnited States _xEvaluation.
650		0	_aOpioid abuse _zUnited States.
650		0	_aDrugs _xPrescribing _xCorrupt practices _zUnited States.
655		7	_aLegislative hearings. _2lcgft
942			_2sudocs _c8